GlassScriptPhysician profile
Ira Zucker
NPI 1730160870
$1,541.30
in general payments reported to CMS, 2019-2025
29 companies · $258 in 2025
The $258 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $179 · 2020: $56.61 · 2021: $76.62 · 2022: $127 · 2023: $524 · 2024: $319 · 2025: $258.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,085 · Education: $16.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,084.78 |
| Education | $16.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $205.00 | 2023-2024 | Signia, Appose Ulc, Minimed 780g |
| Ferring Pharmaceuticals INC. | $173.54 | 2022-2023 | Rebyota |
| Takeda Pharmaceuticals U.S.A., INC. | $126.51 | 2019-2025 | Entyvio |
| Amgen INC. | $116.62 | 2019-2025 | Evenity, Prolia |
| Asensus Surgical, INC. | $100.68 | 2023-2024 | Senhance |
| Regeneron Healthcare Solutions, INC. | $100.14 | 2019-2025 | Dupixent |
| Janssen Biotech, INC. | $89.28 | 2019-2025 | Tremfya |
| Merck Sharp & Dohme LLC | $84.46 | 2021-2025 | Verquvo, Lagevrio, Dificid |
| Abbvie INC. | $82.57 | 2019-2025 | Rinvoq |
| Alexion Pharmaceuticals, INC. | $61.69 | 2020-2023 | Ultomiris |
| Lilly USA, LLC | $46.85 | 2019-2023 | Mounjaro |
| Glaxosmithkline, LLC. | $45.72 | 2022-2023 | Shingrix, Arexvy, Bexsero |
| Braintree Laboratories, INC. | $32.43 | 2024 | Sutab, Suflave |
| Evoke Pharma, INC. | $25.39 | 2025 | |
| Lexicon Pharmaceuticals, INC. | $19.77 | 2024 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sandoz INC. | $19.75 | 2025 | Jubbonti |
| Inspire Medical Systems, INC. | $19.32 | 2024 | Inspire |
| Alnylam Pharmaceuticals INC. | $18.84 | 2025 | Amvuttra |
| Dynavax Technologies Corporation | $18.44 | 2024 | Heplisav-B |
| Taiho Oncology, INC. | $17.89 | 2023 | |
| Novartis Pharmaceuticals Corporation | $17.41 | 2021 | |
| Celltrion USA INC. | $16.60 | 2024 | Zymfentra |
| Ipsen Biopharmaceuticals, INC | $16.30 | 2025 | Iqirvo |
| Organon LLC | $15.69 | 2023 | Renflexis, Hadlima |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.62 | 2023 | Cyltezo |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.58 | 2019 | |
| Octapharma USA, INC. | $13.85 | 2021 | |
| Pfizer INC. | $13.70 | 2019 | |
| Intercept Pharmaceuticals, INC. | $13.66 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ira Zucker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.